Effect of Curcuminoids on Pharmacokinetics and Pharmacodynamics of Atorvastatin in Hyperlipidemia Rats and Its Potential Mechanism

of atorvastatin in combination group significantly increased both in normal and hyperlipidemia rats (p < 0.01). Pharmacodynamics indexes of all treatment groups were significantly improved. There was no significant difference between AC group and combination group except HDL-C, SOD and liver index. In conclusion, CURs combined with atorvastatin could not effectively enhance the lipid-lowering effect or alleviate liver damage. However, CURs could inhibit CYP3A2 activity in rats and increase plasma exposure of atorvastatin, which might increase the risk of HDIs. The findings provided new insight into the combination of CURs and atorvastatin in treating hyperlipidemia.